Up 20% in 1 Month, Is This Stock a Buy?
The pandemic isn't over -- much as we might wish it were. An ongoing surge in coronavirus cases is pouring cold water on these hopes. We recently got a stark reminder that the disease spares nobody after Jill Biden, the wife of U.S. President Joe Biden, tested positive for COVID-19.
Many of those biotechs on the front lines of the fight against the coronavirus seem to be coming back to life after their shares got hammered over the past year or more. One of them is (NASDAQ: NVAX), one of the few companies with an approved or authorized COVID-19 vaccine in circulation in the U.S.
Novavax's shares are up by 21% in the past month alone, but should investors be rushing to invest in this company?
Source Fool.com
Novavax Inc. Aktie
10,54 €
1,39 %
Leichtes Buy-Überwiegen bei Novavax Inc. im Vergleich zu Sell-Einschätzungen.
Das von der Community festgelegte Kursziel für Novavax Inc. von 22 € würde den aktuellen Kurs von 10.54 € mehr als verdoppeln.
